Biospecimen Collection (NCT06821997)

Name: Biospecimen Collection trial for Borderline Resectable Pancreatic Ductal Adenocarcinoma (NCT06821997)
Uploaded: 2026-10-31T21:32:00.069Z
Duration: 1 min 16 s
Description: Biospecimen Collection trial for Borderline Resectable Pancreatic Ductal Adenocarcinoma (NCT06821997). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06821997.

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial: a one-minute explainerNCT068219971 min

Biospecimen Collection trial for Borderline Resectable Pancreatic Ductal Adenocarcinoma (NCT06821997). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with borderline-resectable pancreatic ductal adenocarcinoma who have not received chemotherapy or radiation for it.

The idea: NALIRIFOX combines liposomal irinotecan, oxaliplatin, leucovorin and fluorouracil before surgery. Irinotecan, oxaliplatin and fluorouracil interfere with cancer-cell DNA or its production. Treatment uses four to eight two-week cycles, then surgery and up to four further cycles. Researchers examine how much cancer remains in removed tissue.

This phase 2 study plans 20 patients. Christos Fountzilas leads it at Roswell Park in Buffalo, the single recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.